Marshall Wace, LLP Compugen LTD Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.57 - $3.33 $21,061 - $44,671	13,415 New	13,415 $25,000
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $1.55 Million - $2.6 Million	-561,335 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.09 - $7.16 $2.23 Million - $3.9 Million	544,853 Added 3305.75%	561,335 $2.41 Million
Q3 2021 Nov 15, 2021	SELL	$5.8 - $8.02 $466,244 - $644,703	-80,387 Reduced 82.99%	16,482 $100,000
Q2 2021 Aug 13, 2021	BUY	$6.87 - $9.16 $388,045 - $517,393	56,484 Added 139.86%	96,869 $802,000
Q1 2021 May 17, 2021	BUY	$7.67 - $13.77 $309,752 - $556,101	40,385 New	40,385 $339,000

13.4M

191K

135K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $152M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.